Table 1.
Baseline Characteristics, comparing eyes with Age-related Macular Degeneration (AMD-CNV) and Polypoidal Choroidal Vasculopathy (PCV).
Table 2.
Initial Treatment Pattern from Baseline to Month 3, comparing eyes with Age-related Macular Degeneration (AMD-CNV) and Polypoidal Choroidal Vasculopathy (PCV).
Table 3.
Cumulative number of Anti-vascular endothelial growth factor (anti-VEGF) injections and follow-up visits to month 12, comparing eyes with Age-related Macular Degeneration (AMD-CNV) and Polypoidal Choroidal Vasculopathy (PCV).
Figure 1.
Mean visual acuity of all treated eyes from baseline to month 12.
The number of eyes with OCT available at each timepoint is indicated by n.VA Visual acuity; SE standard error.
Table 4.
Visual Acuity and Optical Coherence Tomography Central Macular Thickness at Month 3 and Month 12, stratified by Diagnosis.
Figure 2.
Distribution of Initial Treatment Modalities by diagnosis of Age-related Macular Degeneration (AMD-CNV) (left) and Polypoidal Choroidal Vasculopathy (PCV) (right).
Table 5.
Comparison of Patient Characteristics and Anti-VEGF Utilization during the First Year of Treatment.